Close

Anti-C32 Phosphomycoketide T cell receptor (DN6), pCDTCR1 (TCR-YC0193)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The CD4−CD8-T cell line DN6 represented a highly useful reporter line to detect new kinds of CD1c-presented antigens because its activation was entirely dependent on, and specific for, CD1c. DN6 was specifically activated by lipid extracts of medically important mycobacteria, like M. tuberculosis and Mycobacterium avium, but not soil-dwelling mycobacteria or other bacteria such as Rhododoccus equi, Nocardia farcinica, or Escherichia coli.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C32 Phosphomycoketide
  • Target Species
  • Mycobacterium tuberculosis
  • Epitope
  • C32 phosphomycoketide
  • Format
  • Non-Modified TCR
  • Allele
  • human CD1c
  • Targeting Diseases
  • Infectious disease
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • DN6
  • Host Species
  • Human

Target

  • Introduction
  • That lipids would function as antigens by simultaneously binding to CD1c and the TCR has been a leading candidate mechanism for recognition, based on analogy to MHC, CD1d, and CD1b. However, bacterial lipids also cause stimulation of T cells by up-regulating CD1c expression, secreting IL-12, or by TLR-mediated triggering of endogenous lipid production.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-C32 Phosphomycoketide T cell receptor (DN6), pCDTCR1 (TCR-YC0193). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.